Acura Pharmaceuticalsincis A Specialty Pharmaceutical Company Engaged In Theresearchdevelopment And Commercialization Of Technologies And Products Intended To Address Medication Abuseand Misusewehavediscovered And Developed Threeproprietary Technology Platforms To Address Abuseand Misuseacross Multiplefronts Aeclimitxa C Technology Is Designed To Retard Thereleaseof Activedrug Ingredients When An Excess Number Of Tablets Areingested In 2014Wewereawarded A $ 00 000 Grant From Thenational Instituteon Drug Abuseto Advanceearly Stagedevelopment Of Our Limitx Technology Aec Aversionatechnology Is A Patented Composition Of Commonly Used Activeand Inactivepharmaceutical Ingredients Providing Abusedeterrent Features To Discouragecommon Methods Of Pharmaceutical Product Misuseand Abusewhileproviding Effectivepain Relief Oxaydoatabletsoxycodonehclcii Is Thefirst Approved Product Using Aversionain Theunited States On January 72015Weentered Into A Collaboration And Licenseagreement With Egalet Usincgranting To Egalet Exclusiveworldwiderights To Manufactureand Commercializeoxaydo Oxaydo Is Approved By Theu Sfood And Drug Administration For Marketing In Theunited States In 5Mg And 7 5Mg Strengths Egalet Launched Oxaydo In Theunited States Latein Thethird Quarter Of 2015 Aecimpedeatechnology Is A Combination Of Inactiveingredients That Prevent Theextraction Or Disrupt Thedirect Conversion Of Pseudoephedrinefrom Commonly Used Decongestant Tablets Into Methamphetaminenexafedadecongestant With Impedetechnology Was Launched Into Theunited States Market In December 2012 Followed By Nexafed Sinus Pressurepain In February 2015Wehavemultiplepseudoephedrineproducts In Development Utilizing Impedetechnology
